Pharvaris NV (PHVS)$29.68

Market Cap: 1.02 BCurrency: USD

Static fundamentals, valuation context, and investor signals for Pharvaris NV (PHVS).

HEALTHCARE

BIOTECHNOLOGY

Valuation

N/A

EV/FCF, N/A FCF yield

Quality

N/A

ROIC, N/A FCF margin

Growth

N/A

5Y sales (revenue) CAGR

Balance sheet

N/A

Debt/equity, N/A current ratio

Superinvestors

Top: Viking Global Investors (0.3%)

No strong positive screening signals were detected from the checked-in dataset.

Annual data: 0 periods

Quarterly data: 6 periods

Stock snapshot: May 24, 2026

Static dataset: May 25, 2026

Build-time composite score for PHVS.

Grade F

/ 100

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


PHVS Target	Pharvaris NV	$1.0B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RCKT	Rocket Pharmaceuticals Inc.	$838.3M	-1.5x	-4.0x	-80.5%	N/A	N/A	N/A	N/A	N/A
NUVB	Nuvation Bio Inc.	$808.4M	-7.9x	-4.0x	-58.0%	N/A	-275.7%	N/A	N/A	N/A
MESO	Mesoblast Ltd Spon ADR	$1.4B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADPT	Adaptive Biotechnologies Corp.	$1.5B	-35.6x	-29.7x	-27.2%	23.0%	-17.7%	N/A	N/A	N/A
TRVI	Trevi Therapeutics Inc.	$667.1M	-44.2x	-15.4x	-23.3%	N/A	N/A	N/A	N/A	N/A
EWTX	Edgewise Therapeutics Inc.	$1.7B	-20.1x	-11.6x	-0.0%	N/A	N/A	N/A	N/A	N/A
TVTX	Travere Therapeutics Inc.	$1.9B	-153.2x	47.9x	-22.2%	19.9%	7.7%	N/A	N/A	N/A
NAMS	Newamsterdam Pharma Co Nv	$2.2B	-20.6x	-11.7x	-29.7%	N/A	-657.8%	N/A	N/A	N/A

Financial Charts

No financial data available for PHVS (annual).

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
Viking Global Investors Viking Global Investors	3,653,310	$103M	0.29%	0.0%